Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model
Although several agents have been identified to provide therapeutic benefits in Huntington disease (HD), the number of conventionally used treatments remains limited and only symptomatic. Thus, it is plausible that the need to identify new therapeutic targets for the development of alternative and m...
Main Authors: | Alba Di Pardo, Giuseppe Pepe, Salvatore Castaldo, Federico Marracino, Luca Capocci, Enrico Amico, Michele Madonna, Susy Giova, Se Kyoo Jeong, Bu-Mahn Park, Byeong Deog Park, Vittorio Maglione |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2019.00100/full |
Similar Items
-
Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington's disease
by: A. Di Pardo, et al.
Published: (2020-09-01) -
K6PC-5 Activates SphK1-Nrf2 Signaling to Protect Neuronal Cells from Oxygen Glucose Deprivation/Re-Oxygenation
by: Hua Liu, et al.
Published: (2018-11-01) -
Rôle de la Sphingosine 1 Phosphate dans la pathogénie de l'arthrose
by: Cherifi, Chahrazad
Published: (2017) -
Lentivirus-mediated siRNA knockdown of SPHK1 inhibits proliferation and tumorigenesis of neuroblastoma
by: Su L, et al.
Published: (2018-10-01) -
MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1
by: Xiao-Zheng Cao, et al.
Published: (2019-01-01)